First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4+bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) Meeting Abstract

  


Authors: Cassidy, J.; Clarke, S.; Rubio, E. D.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T. S.; Saltz, L.
Abstract Title: First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4+bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC)
Meeting Title: 30th Congress of the European Society for Medical Oncology
Keywords: fluorouracil; oxaliplatin; leucovorin
Journal Title: Annals of Oncology
Volume: 17
Issue: Suppl.9
Meeting Dates: 2006 Sep 29-Oct 3
Meeting Location: Istanbul, Turkey
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2006-01-01
Language: English
ACCESSION: WOS:000248078900004
PROVIDER: wos
Notes: --- - Meeting Abstract: 382 - 30th Congress of the European-Society-for-Medical-Oncology - SEP 29-OCT 03, 2006 - Istanbul, TURKEY - "9" - "Source: Wos"